Literature DB >> 1679339

Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis.

M Kamori1, M Hagihara, T Nagatsu, H Iwata, T Miura.   

Abstract

We examined the activities of peptidases in the synovial membrane from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Dipeptidyl peptidase II (DPP II), prolyl endopeptidase (PEP), and collagenase-like peptidase (CLP) activities were higher in knee joint synovial membrane from patients with RA than in that from patients with OA. DPP II and PEP activities in knee joint synovial membrane of patients with RA increased in parallel with the increase in joint fluid volume, whereas DPP IV activity decreased in parallel with the increase in joint fluid volume. These results suggest that these peptidases in the synovial membrane may play some role in immunological disturbances in the joints of patients with RA. Measurement of these peptidases in synovial membrane may be useful in the diagnosis of the severity of local joint inflammation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679339     DOI: 10.1016/0885-4505(91)90016-e

Source DB:  PubMed          Journal:  Biochem Med Metab Biol        ISSN: 0885-4505


  23 in total

1.  Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.

Authors:  Khalaf Kridin; Kyle Amber; Mogher Khamaisi; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

2.  Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen.

Authors:  Philip J O'Reilly; Matthew T Hardison; Patricia L Jackson; Xin Xu; Robert J Snelgrove; Amit Gaggar; F Shawn Galin; J Edwin Blalock
Journal:  J Neuroimmunol       Date:  2009-10-28       Impact factor: 3.478

Review 3.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

Review 4.  Extracellular signaling in Dictyostelium.

Authors:  Kristen M Consalvo; Ramesh Rijal; Yu Tang; Sara A Kirolos; Morgan R Smith; Richard H Gomer
Journal:  Int J Dev Biol       Date:  2019       Impact factor: 2.203

Review 5.  Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.

Authors:  Annamaria Mascolo; Concetta Rafaniello; Liberata Sportiello; Maurizio Sessa; Daniela Cimmaruta; Francesco Rossi; Annalisa Capuano
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

6.  Role of the neutrophil chemorepellent soluble dipeptidyl peptidase IV in decreasing inflammation in a murine model of arthritis.

Authors:  Sarah E Herlihy; Monica L Brown; Darrell Pilling; Brad R Weeks; Linda K Myers; Richard H Gomer
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

7.  Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis.

Authors:  Hasan Ulusoy; Ayhan Kamanli; Necip Ilhan; Omer Kuru; Sule Arslan; Gokhan Alkan; Salih Ozgocmen
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

8.  Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.

Authors:  Jofre Tenorio-Laranga; Francisco Coret-Ferrer; Buenaventura Casanova-Estruch; María Burgal; J Arturo García-Horsman
Journal:  J Neuroinflammation       Date:  2010-04-06       Impact factor: 8.322

9.  Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides.

Authors:  J M Bathon; D Proud; S Mizutani; P E Ward
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Dipeptidyl peptidase IV is a human and murine neutrophil chemorepellent.

Authors:  Sarah E Herlihy; Darrell Pilling; Anu S Maharjan; Richard H Gomer
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.